MR1 and cancer: Given most studies to date with MR1-reactive T cells rely on MR1*01 overexpressing lines as targets, we next investigated whether 7G5.TCR-T could react to MR1*04-negative cancer lines engineered to express supraphysiological levels of the MR1*01 allele.